Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) and Denali Therapeutics (NASDAQ:DNLI – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.
Volatility & Risk
Ascendis Pharma A/S has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Ascendis Pharma A/S and Denali Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ascendis Pharma A/S | 0 | 1 | 18 | 1 | 3.00 |
| Denali Therapeutics | 1 | 2 | 13 | 0 | 2.75 |
Valuation and Earnings
This table compares Ascendis Pharma A/S and Denali Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ascendis Pharma A/S | $814.57 million | 17.05 | -$258.00 million | $12.89 | 17.28 |
| Denali Therapeutics | $3.60 million | 828.06 | -$512.54 million | ($2.84) | -6.57 |
Ascendis Pharma A/S has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ascendis Pharma A/S and Denali Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ascendis Pharma A/S | 70.99% | 32.54% | 7.71% |
| Denali Therapeutics | N/A | -55.27% | -44.24% |
Institutional & Insider Ownership
92.9% of Denali Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Ascendis Pharma A/S beats Denali Therapeutics on 11 of the 15 factors compared between the two stocks.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
About Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson’s disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
